The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.

开始日期2008-10-01

申办/合作机构

Molecular Targeting Technologies, Inc.

[+5]

100 项与 99m Tc-glucarate(Molecular Targeting Technologies, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 99m Tc-glucarate(Molecular Targeting Technologies, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 99m Tc-glucarate(Molecular Targeting Technologies, Inc.) 相关的专利（医药）

登录后查看更多信息

项与 99m Tc-glucarate(Molecular Targeting Technologies, Inc.) 相关的文献（医药）

2012-04-01·World Journal of Nuclear Medicine

99m Tc glucarate as a potential radiopharmaceutical agent for assessment of tumor viability: From bench to the bed side

Article

作者: Dondi, M. ; Gambini, J. ; Gupta, A. ; Savio, E. ; Solanki, K. ; Alonso, O. ; Doval, Dinesh ; Choudhury, Partha ; Sharma, P.

Several radiotracers have been used for assessing cell death, whether by necrosis or apoptosis. 99m Tc glucarate, which has initially been reported to be concentrating/accumulating in myocardial infarction or zones of cerebral injury, has also shown some tumor-seeking properties in a few preliminary studies. Under International Atomic Energy Agency (IAEA)′s coordinated research program, we report here the standardization, quality control, and clinical evaluation (detection, evaluation of response, and comparison with 18 F Fluorodeoxyglucose) of this tracer in well-characterized lung cancer and head neck malignancies in a single-arm prospective observational study. Forty-seven patients (29 inoperable lung carcinoma and 18 head and neck malignancies) were prospectively enrolled and underwent 99m Tc glucarate imaging [whole body planar and single-photon emission computed tomography of the region of interest] 4-5 hours after injection of 20 mCi of the radiopharmaceutical. Excellent 99m Tc glucarate concentration was noted in the target lesion in lung cancer and head and neck malignancies. The sensitivity was found to be better in lung cancer. Avid concentration of tracer was seen in the metastatic sites. During response evaluation, the glucarate concentration correlated well with the clinical and other radiological findings. 99m Tc glucarate showed avid concentration of tracer in the tumor, suggesting it to be a potential tumor imaging agent which can be used for detection and assessment of therapeutic response in malignancy.

2011-02-01·Nuclear Medicine and Biology4区 · 医学

Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model

4区 · 医学

Article

作者: Figueroa, Said Daibes ; Zhang, Xiuli ; Ma, Lixin ; Deutscher, Susan L. ; Cabral, Pablo ; Alonso, Omar ; Quinn, Thomas P. ; Savio, Eduardo ; Gambini, Juan Pablo

INTRODUCTIONThe use of [(99m)Tc]glucarate has been reported as an infarct-avid agent with the potential for very early detection of myocardial infarction. [(99m)Tc]Glucarate has also been postulated as an agent for non-invasive detection of tumors. The aim of our study was to develop a Glucarate kit and evaluate [(99m)Tc]glucarate as a potential cancer imaging agent in female SCID mice bearing human MDA-MB-435 breast tumors.METHODSGlucarate in a kit formulation was labeled with (99m)Tc and evaluated for radiolabelling efficiency and radiochemical purity. The Glucarate kit stability was assessed by monthly quality controls. The pharmacokinetics of [(99m)Tc]glucarate were determined in female SCID mice bearing MDA-MB-435 human breast carcinoma tumors at 0.5, 1, 2, 4 and 24 h. Nuclear imaging studies were performed with a micro-single photon emission tomography (SPECT)/computed tomography (CT) system at 2 h post injection, while magnetic resonance imaging (MRI) was employed for tumor morphology analysis and metastatic deposit localization.RESULTSThe Glucarate kits exhibited a stable shelf life of 6 months. [(99m)Tc]Glucarate was obtained with radiochemical purity greater than 95%. Biodistribution studies demonstrated moderate tumor uptake coupled with high renal clearance. Tumor-to-muscle ratios were 4.85 and 5.14 at 1 and 4 h post injection. MRI analysis showed tumors with dense cellular growth and moderate central necrosis. [(99m)Tc]Glucarate uptake in the primary MDA-MB-435 shoulder tumors and metastatic lesions were clearly visualized with micro-SPECT/CT imaging.CONCLUSIONSSelective tumor uptake and rapid clearance from nontarget organs makes [(99m)Tc]glucarate a potential agent for breast cancer imaging that awaits validation in a clinical trial.

2010-10-01·European Journal of Nuclear Medicine and Molecular Imaging1区 · 医学

99mTc-glucarate kinetics differentiate normal, stunned, hibernating, and nonviable myocardium in a perfused rat heart model

1区 · 医学

Article

作者: Liu, Zhonglin ; Okada, Robert D. ; Beju, Delia ; Khaw, Ban An ; Okada, David R. ; Johnson, Gerald III

PURPOSE(99m)Tc-glucarate is an infarct-avid imaging agent. However, patients may have mixtures of normal, irreversibly injured, stunned, and hibernating myocardium. The purposes were to determine (99m)Tc-glucarate uptake and clearance kinetics in these four conditions, and its ability to determine the extent of injury.METHODSTwenty-two perfused rat hearts were studied: controls (n = 5), stunned (n = 5; 20-min no-flow followed by 5-min reflow), hibernating (n = 6; 120-min low flow at 4 ml/min), and ischemic-reperfused (n = 6; 120-min no-flow followed by reflow). (99m)Tc-glucarate was then infused. Tracer activity was monitored using a NaI scintillation detector and a multichannel analyzer. Creatine kinase, electron microscopy, and triphenyltetrazolium chloride determined viability.RESULTS(99m)Tc-glucarate 10-min myocardial uptake was significantly greater in ischemic-reperfused (2.50 +/- 0.09) (cpm, SEM) than in control (1.74 +/- 0.07), stunned (1.68 +/- 0.11), and hibernating (1.59 +/- 0.11) (p < 0.05). Tracer retention curves for ischemic-reperfused were elevated at all time points as compared with the other groups. (99m)Tc-glucarate 60-min myocardial uptake was significantly greater in ischemic-reperfused (7.60 +/- 0.63) than in control (1.98 +/- 0.15), stunned (1.79 +/- 0.08), and hibernating (2.33 +/- 0.15) (p < 0.05). The 60-min well-counted tracer activity ratio of ischemic-reperfused to control was 9:1 and corroborated the NaI detector results. Creatine kinase, triphenyltetrazolium chloride, and electron microscopy all demonstrated significantly greater injury in ischemic-reperfused compared to the other groups. An excellent correlation was observed between viability markers and tracer activity (r = 0.99 triphenyltetrazolium chloride; r = 0.90 creatine kinase).CONCLUSION(99m)Tc-glucarate activity continually and progressively increased in irreversibly injured myocardium. (99m)Tc-glucarate uptake was strongly correlated with myocardial necrosis as determined by three independent assessments of viability. There were minimal and similar (99m)Tc-glucarate uptakes in control, stunned, and hibernating myocardium.

100 项与 99m Tc-glucarate(Molecular Targeting Technologies, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏损伤	临床3期	德国	Molecular Targeting Technologies, Inc.	2022-09-27
肿瘤	临床3期	德国	Molecular Targeting Technologies, Inc.	2022-09-27
Acrocallosal综合征	药物发现	美国	Molecular Targeting Technologies, Inc.	2008-10-01
急性冠状动脉综合征	药物发现	美国	Molecular Targeting Technologies, Inc.	2008-10-01
急性心肌梗塞	药物发现	美国	Molecular Targeting Technologies, Inc.	2008-10-01
胸痛	药物发现	美国	Molecular Targeting Technologies, Inc.	2008-10-01
冠心病	药物发现	美国	Molecular Targeting Technologies, Inc.	2008-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2014	N/A	非小细胞肺癌	-	99mTc-glucarate (H292 lung adenocarcinoma cell line)	繭構鏇觸願顧積窪夢築(淵襯積艱齋齋糧獵艱積) = 遞餘憲鹽艱淵簾蓋鹽襯範艱糧遞獵築醖齋衊製 (憲餘糧製衊衊鹽鹹獵鏇 ) 更多	-	2014-11-05
				99mTc-glucarate (A549 lung adenocarcinoma cell line)	繭構鏇觸願顧積窪夢築(淵襯積艱齋齋糧獵艱積) = 範網鬱鹹簾鏇糧鹽築衊範艱糧遞獵築醖齋衊製 (憲餘糧製衊衊鹽鹹獵鏇 ) 更多